Thus, it might be an effective combinatorial treatment with PARP1 and CCR2 inhibitors to achieve better outcomes where CCL2 levels are determined to be high, particularly in breast cancer, as well as other solid tumors. The gene discussed is CCL2; the disease is breast cancer.